Skip to content

Calciphylaxis (Calcific Uremic Arteriolopathy): Excruciating Violaceous Retiform Plaques, Black Necrotic Eschars in Dialysis Patients, and Sodium Thiosulfate

Emergency numbers differ by country. This page uses 911, the number for the United States and Canada. Many other countries use 112, 999, or another number. Find the number for your country.

Calciphylaxis, medically designated as calcific uremic arteriolopathy (CUA) when it occurs in patients with end-stage kidney disease, is a devastating, life-threatening vascular calcification syndrome characterized by medial calcification, subintimal fibrosis, and acute thrombotic occlusion of small dermal and subcutaneous arterioles (ranging from 40 to 600 micrometers in diameter). Unlike ordinary atherosclerotic peripheral arterial disease that narrows large named conduit arteries in the legs while leaving pedal pulses weak or absent, calciphylaxis strikes the microscopic arteriolar network embedded deep within adipose-rich subcutaneous fat tissues (the abdomen, panniculus, thighs, buttocks, and breasts) or distal extremities while large-vessel ankle and foot pulses often remain completely palpable. In a patient on chronic hemodialysis or peritoneal dialysis, or in a patient with normal renal function taking warfarin (non-uremic calciphylaxis), the loss of natural vascular calcification inhibitors, specifically carboxylated Matrix Gla Protein (MGP) and hepatic fetuin-A, combined with hyperphosphatemia, hypercalcemia, elevated calcium-phosphate product, vitamin D analogs (calcitriol, paricalcitol), calcium-based phosphate binders (calcium acetate, calcium carbonate), and repetitive subcutaneous injections (insulin or heparin) triggers phenotypic transformation of vascular smooth muscle cells into bone-forming osteoblast-like cells. Once the calcified arteriolar lumen is sealed shut by an acute fibrin thrombus, the overlying skin and fat suffer catastrophic infarction. Clinically, calciphylaxis announces itself with excruciating, burning, 10-out-of-10 ischemic skin pain that frequently precedes visible skin necrosis by days, rapidly evolving from mottled violaceous retiform (net-like) purpura and rock-hard, woody subcutaneous nodules into star-shaped (stellate), black, leathery necrotic eschars surrounded by dusky violaceous borders. Because ulcerated calciphylaxis eschars sit directly over devitalized fat, secondary bacterial invasion leads to fulminant wound sepsis, driving a historical one-year mortality rate of 50 to 80 percent. If a dialysis patient or warfarin user develops excruciatingly painful purple net-like plaques, woody subcutaneous nodules, or black necrotic skin ulcers, call your local laharana vonjy maika or proceed to an emergency department immediately. Also review our sibling guides on dialysis access AV fistula life-threatening bleed and missed dialysis hyperkalemia, erysipelas vs necrotizing fasciitis vs stasis dermatitis triage, ary sepsis and septic shock recognition.

Your immediate emergency priorities are to immediately discontinue all calcification accelerators, stopping warfarin (switching to a direct oral anticoagulant like apixaban or low-molecular-weight heparin after specialist review, while giving intravenous Vitamin K1 to reactivate Matrix Gla Protein), stopping all calcium-containing phosphate binders (switching to non-calcium binders like sevelamer or lanthanum), and stopping active Vitamin D analogs (switching to calcimimetics like cinacalcet or etelcalcetide if severe secondary hyperparathyroidism is present). Simultaneously, clinicians must initiate intravenous Sodium Thiosulfate (typically 25 grams IV infused over the final 30 to 60 minutes of each hemodialysis session three times weekly), intensify hemodialysis with a low-calcium dialysate bath, and avoid aggressive deep surgical debridement or traumatic deep punch biopsies during the acute inflammatory phase where pathergy and microvascular ischemia cause wounds to expand catastrophically.

Ataovy izao izao

  1. Seek immediate Hospital Admission or Emergency Nephrology and Dermatology Evaluation if a patient on dialysis (or taking warfarin) develops excruciatingly painful violaceous mottled skin plaques, rock-hard subcutaneous fat nodules, or black necrotic eschars. Dial 911 in the United States and Canada, 999 in the United Kingdom, 112 across the European Union, 000 in Australia, or consult our global directory of laharana vonjy maika. If the patient also has fever, rigors, hypotension, confusion, or foul purulent drainage from an ulcerated eschar, declare a medical sepsis emergency immediately.
  2. Audit and STOP the "Big Four" Pharmacological Accelerators of Calciphylaxis Immediately Upon Hospital Arrival:
  3. STOP Warfarin (Vitamin K Antagonists): Warfarin blocks the gamma-carboxylation of Matrix Gla Protein (MGP), the body's most potent endogenous inhibitor of arteriolar medial calcification. Transition the patient to a non-vitamin-K oral anticoagulant (such as apixaban at renal-adjusted dosing) or therapeutic heparin in consultation with hematology and nephrology, and administer Vitamin K1 (phytonadione, 10 mg orally or IV three times weekly) to restore active carboxylated MGP.
  4. STOP All Calcium-Based Phosphate Binders (PhosLo [calcium acetate], Tums [calcium carbonate]) and Calcium Supplements: Switch immediately to non-calcium-containing phosphate binders such as sevelamer carbonate (Renvela), lanthanum carbonate (Fosrenol), or sucroferric oxyhydroxide (Velphoro).
  5. STOP All Active Vitamin D Analogs (Calcitriol, Paricalcitol, Doxercalciferol) and High-Dose Ergocalciferol/Cholecalciferol: Vitamin D receptor agonists increase intestinal calcium and phosphate absorption and directly stimulate vascular smooth muscle calcification. If the patient has severe secondary hyperparathyroidism (iPTH > 300 pg/mL), switch to a calcimimetic (oral cinacalcet [Sensipar] or intravenous etelcalcetide [Parsabiv]) or arrange urgent parathyroidectomy.
  6. STOP Intravenous Iron Dextran/Sucrose and Subcutaneous Injections into Affected Fat Pads: Iron overload catalyzes local hydroxyl free-radical injury in ischemic dermis, and repetitive subcutaneous insulin or heparin injections into the abdominal panniculus or thighs trigger local fat trauma and pathergic arteriolar thrombosis. Rotate injections to unaffected lean sites or transition to intravenous infusion while hospitalized.
  7. Initiate Intravenous Sodium Thiosulfate (Na2S2O3) at 25 Grams IV Three Times Weekly (During the Final 60 Minutes of Each Hemodialysis Session): Intravenous Sodium Thiosulfate (STS) is the cornerstone systemic rescue therapy for acute calciphylaxis. It chelates insoluble tissue calcium deposits into ultra-soluble calcium thiosulfate (which is 250-fold to 100,000-fold more soluble in water than calcium phosphate or calcium oxalate and is rapidly cleared across the hemodialysis membrane), acts as a potent free-radical antioxidant that restores endothelial nitric oxide synthase (eNOS), and induces direct arteriolar vasodilation that often reduces excruciating ischemic skin pain within 1 to 2 weeks.
  8. Watch for and Manage the Two Dangerous Complications of IV Sodium Thiosulfate: High Anion Gap Metabolic Acidosis and Severe Nausea/Hypotension:
  9. When sodium thiosulfate is metabolized by the liver into thiosulfuric acid and sulfate anions, it generates a profound high anion gap metabolic acidosis (often dropping serum bicarbonate below 14 to 16 mmol/L). Check a basic metabolic panel and anion gap before each dialysis session and increase the hemodialysis bath bicarbonate concentration (or administer oral sodium bicarbonate only if volume status permits).
  10. Infusing 25 grams of STS too rapidly (< 30 minutes) causes intractable projectile vomiting, severe nausea, and acute intradialytic hypotension. Always premedicate with IV Ondansetron (4 to 8 mg) or Promethazine 30 minutes prior to infusion, and infuse STS slowly over 60 minutes.
  11. Optimize the Hemodialysis Prescription Immediately: Increase dialysis frequency and duration (for example, 4 to 5 sessions per week of 4 hours each) to aggressively clear serum phosphate and uremic toxins, and switch the dialysate bath to a low-calcium dialysate concentration (1.5 to 2.0 mEq/L, or 0.75 to 1.0 mmol/L) so that calcium is actively diffused out of the patient's bloodstream during dialysis. If the patient is on peritoneal dialysis (PD) (which carries a significantly higher incidence of calciphylaxis due to constant peritoneal glucose degradation products and poor phosphate clearance), strongly consider urgent transition to hemodialysis.
  12. Protect the Ulcerated Skin and Avoid Aggressive Deep Surgical Excision During Active Ischemia (Preventing Pathergic Ulcer Expansion): Unlike necrotizing fasciitis (which requires emergency wide surgical debridement in the operating room), cutting into surrounding ischemic, calcified dermis in active calciphylaxis frequently triggers pathergy and progressive ischemic edge necrosis, creating a massive, unhealable crater. Keep intact black dry eschars clean, dry, and protected unless wet purulent infection develops underneath; when removal of necrotic slough is needed to prevent sepsis, use gentle enzymatic debridement (collagenase), hydrogel autolytic dressings, maggot debridement therapy, or cautious conservative removal of loose devitalized tissue paired with Hyperbaric Oxygen Therapy (HBOT) once arteriolar calcification is being treated.
  13. Provide Aggressive Multimodal Neuropathic and Ischemic Pain Control (Strictly Avoiding Morphine and Meperidine in Dialysis Patients): Calciphylaxis pain is among the most agonizing pain syndromes in medicine, combining deep ischemic tissue infarction with small-fiber neuropathic injury. Never use morphine, codeine, or meperidine in renal failure (their toxic metabolites morphine-6-glucuronide and normeperidine accumulate to lethal levels causing myoclonus, seizures, and respiratory arrest). Instead, use intravenous or transdermal Fentanyl, Methadone, or Buprenorphine (all safe in dialysis with zero active renal metabolites) combined with renal-adjusted Gabapentin (100 to 300 mg post-dialysis) or ketamine infusions.

Why Warfarin Is Strictly Contraindicated in Any Patient with Known or Suspected Calciphylaxis

In normal human arterioles, smooth muscle cells continuously synthesize a small local protein called Matrix Gla Protein (MGP). To prevent calcium and phosphate from crystallizing inside the arterial wall, MGP must first be activated through vitamin K-dependent gamma-carboxylation (the exact same enzymatic step that activates clotting factors II, VII, IX, and X in the liver). When a dialysis patient, or even a patient with normal kidneys, is prescribed warfarin (Coumadin) for atrial fibrillation or a deep vein thrombosis, warfarin blocks Vitamin K epoxide reductase (VKORC1) inside the arteriolar wall, shutting down active carboxylated MGP by over 80 percent. Deprived of its natural calcification shield, the arteriolar media rapidly calcifies into brittle bone, raising the risk of calciphylaxis 3-fold to 10-fold. Stopping warfarin immediately and administering Vitamin K1 (phytonadione) is mandatory on Day 1.

Decision tree: suspected Calciphylaxis (Calcific Uremic Arteriolopathy) vs Warfarin Skin Necrosis vs Necrotizing Fasciitis

flowchart TD
    A["Dialysis Patient (HD/PD) or Warfarin User Presents with Excruciating 10/10 Burning Skin Pain + Violaceous Retiform (Net-Like) Plaques, Woody Subcutaneous Nodules, or Black Stellate Necrotic Eschars on Abdomen, Thighs, Buttocks, or Legs"] --> B{"Step 1: Immediate Sepsis & Necrotizing Fasciitis Screen: Is There Crepitus, Dishwater Fluid, Rapidly Spreading Fascial Bullae, High Fever, or Septic Shock?"}
    B -->|YES: Wet Gangrene / Fulminant Wound Sepsis or Necrotizing Fasciitis| C["Resuscitate with IV Crystalloids + Broad-Spectrum IV Antibiotics (Vancomycin + Cefepime/Piperacillin-Tazobactam + Metronidazole) + Urgent Surgical / Wound Consult for Infected Eschar Drainage"]
    B -->|NO: Dry Leathery Black Eschar or Intact Violaceous Plaque / Woody Subcutaneous Nodule| D["Step 2: Bedside Vascular & Medication Audit + Plain Soft-Tissue Radiographs (Mammography-Technique X-Rays) or Bone Scintigraphy"]
    C --> D
    D --> E{"Check Timing of Warfarin Initiation (Did Necrosis Evolve Within Day 3 to Day 10 of Starting Warfarin Without Heparin Bridge?)"}
    E -->|YES: Acute Onset Day 3 to 8 of Warfarin + Rapid Protein C Drop| F["ACUTE WARFARIN-INDUCED SKIN NECROSIS (Microvascular Venular Thrombosis): Stop Warfarin + Give IV Vitamin K + Start Therapeutic IV Unfractionated Heparin + Fresh Frozen Plasma / Protein C Concentrate"]
    E -->|NO: Chronic Warfarin Use (> Months/Years) OR Dialysis / ESRD Patient with High Phosphate/PTH + Fine Net-Like Arteriolar Calcification on X-Ray| G["CONFIRMED CALCIPHYLAXIS (Calcific Uremic Arteriolopathy - CUA)"]
    G --> H["STEP 1 (Halt All Accelerators Immediately): 1. STOP Warfarin (Give Vitamin K1 10 mg 3x/wk; switch to Apixaban if anticoagulation needed); 2. STOP Calcium Phosphate Binders (Switch to Sevelamer/Lanthanum); 3. STOP Calcitriol/Vitamin D Analogs; 4. STOP Iron & SubQ Injections in Plaques"]
    H --> I["STEP 2 (Start Definitive Calcium-Chelating & Vasodilatory Therapy): Administer IV SODIUM THIOSULFATE (25 Grams IV Over Final 60 Min of Each Hemodialysis Session 3x/Week) + Premedicate with IV Ondansetron"]
    I --> J["STEP 3 (Optimize Dialysis & Parathyroid Axis): Increase Hemodialysis to 4-5x/Week with LOW-CALCIUM Dialysate Bath (1.5 mEq/L); If iPTH > 300 pg/mL, Start Cinacalcet / Etelcalcetide or Arrange Urgent Parathyroidectomy"]
    J --> K["STEP 4 (Safe Analgesia & Wound Care): Use Fentanyl, Methadone, or Buprenorphine + Post-HD Gabapentin (NEVER Morphine/Meperidine); Avoid Deep Surgical Excision of Dry Eschars; Consider Hyperbaric Oxygen (HBOT) & Intralesional Sodium Thiosulfate"]

Pathophysiology: how vascular smooth muscle cells turn into bone and why adipose tissue is the primary target

For decades, physicians assumed that calciphylaxis was simply passive chemical precipitation of calcium and phosphate when the serum calcium-phosphate product (Ca x PO4) exceeded 55 to 70 mg squared per dL squared. Modern vascular biology has proven that calciphylaxis is actually an active, cell-mediated osteogenic transformation followed by an acute thrombotic second hit:

THE TWO-HIT PATHOPHYSIOLOGY OF CALCIPHYLAXIS (CUA)
=======================================================================
[HIT 1: CHRONIC ARTERIOLAR MEDIAL CALCIFICATION & INTIMAL HYPERPLASIA]
   * Triggers in ESRD / Dialysis / Non-Uremic Warfarin Patients:
     1. Loss of Active Carboxylated Matrix Gla Protein (MGP) -> Warfarin
        or Vitamin K deficiency disables the local arteriolar shield.
     2. Loss of Systemic Fetuin-A (Negative acute-phase liver protein)
        & Inorganic Pyrophosphate (PPi) -> Fails to clear calciprotein
        particles from the bloodstream.
     3. Hyperphosphatemia + Calcium Binders + Calcitriol + High PTH ->
        Phosphate enters arteriolar Smooth Muscle Cells via Pit-1
        cotransporters, activating the bone transcription factor RUNX2
        (Cbfa1) and BMP-2 (Bone Morphogenetic Protein-2).
   * Result: Arteriolar smooth muscle cells transdifferentiate into
     OSTEOBLAST-LIKE CELLS that lay down concentric hydroxyapatite bone
     crystals in the tunica media of 40-to-600-micron subcutaneous
     arterioles, while subintimal fibrosis narrows the lumen by 80%.
                                  |
                                  v
[HIT 2: ACUTE ENDOTHELIAL THROMBOSIS & INFARCTION OF SUBCUTANEOUS FAT]
   * Local Triggers: Repetitive subcutaneous insulin/heparin injections,
     minor skin trauma (pathergy), iron overload, hypercoagulability
     (Protein C/S deficiency, lupus anticoagulant), or hypotension.
   * Result: An acute FIBRIN THROMBUS plugs the rigid, calcified
     micro-arteriole -> Complete ischemic infarction of the overlying
     adipose lobules and dermis -> Excruciating 10/10 ischemic nerve
     pain -> Violaceous retiform purpura -> Black stellate eschar.
=======================================================================

Central (Adipose-Rich) vs. Peripheral (Acral) Calciphylaxis: Clinical Patterns and Prognosis

Clinicians classify calciphylaxis into two distinct anatomical distributions that carry very different survival outcomes: 1. Central (Proximal / Adipose-Rich) Calciphylaxis (70% to 80% of Cases): Strikes areas with thick subcutaneous adipose tissue, specifically the abdominal panniculus, medial and lateral thighs, buttocks, flanks, and female breasts. Because adipose lobules are supplied by long, tortuous, end-arteriolar vessels with poor collateral circulation and because mature adipocytes secrete pro-calcific adipokines (leptin, TNF-alpha, and IL-6) that accelerate vascular smooth muscle RUNX2 activation, central fat pads are uniquely vulnerable. Central calciphylaxis carries the highest mortality rate (60% to 80% at 1 year) because large abdominal and thigh ulcers rapidly become colonized by enteric Gram-negative bacteria and Staphylococcus aureus, leading to fatal bacteremia. 2. Peripheral (Distal / Acral) Calciphylaxis (20% to 30% of Cases): Strikes lean distal areas with minimal subcutaneous fat, including the calves, shins, ankles, toes, fingers, and occasionally the glans penis (penile calciphylaxis). Peripheral lesions carry a relatively lower (though still serious) mortality rate of 20% to 40%, though digital or penile gangrene requires careful differentiation from large-vessel atherosclerotic peripheral arterial disease (PAD) and cholesterol crystal embolization. 3. Non-Uremic Calciphylaxis (NUC, 10% to 15% of Cases): Occurs in patients with normal kidney function (eGFR > 60 mL/min) driven by chronic warfarin use, primary hyperparathyroidism, autoimmune diseases on chronic corticosteroids, or alcoholic cirrhosis (impaired hepatic synthesis of fetuin-A and Protein C/S).

Side-by-side differential diagnosis: Calciphylaxis vs Warfarin-Induced Skin Necrosis vs Necrotizing Fasciitis vs Cholesterol Embolization vs Pyoderma Gangrenosum

Because misdiagnosing calciphylaxis as pyoderma gangrenosum (and giving high-dose systemic corticosteroids that accelerate calcification and sepsis) or misdiagnosing it as necrotizing fasciitis (and performing wide radical excisional debridement that triggers catastrophic non-healing pathergy) can cost the patient their life, use this clinical comparison table at the bedside:

Clinical, Vascular & Diagnostic Feature Calciphylaxis (Calcific Uremic Arteriolopathy - CUA) Acute Warfarin-Induced Skin Necrosis (WISN) Necrotizing Fasciitis (Type I Polymicrobial / Type II Group A Strep) Cholesterol Crystal Embolization ("Trash Foot" / Blue Toe Syndrome) Pyoderma Gangrenosum (Ulcerative Neutrophilic Dermatosis)
Typical Patient & Primary Trigger Chronic hemodialysis or peritoneal dialysis patient (or non-uremic patient on long-term warfarin, steroids, or with hyperparathyroidism); high PO4/Ca. Patient who started high-dose Warfarin 3 to 10 days ago without a therapeutic heparin bridge (causes acute drop in short-half-life Protein C before Factors II/X fall). Post-surgical wound, penetrating trauma, diabetes, IV drug use, or cirrhosis (Vibrio / Aeromonas / Strep pyogenes). Recent cardiac catheterization, vascular stenting, aortic surgery, or initiation of anticoagulation in a patient with severe aortic atherosclerosis. Patient with Inflammatory Bowel Disease (Ulcerative Colitis / Crohn), Rheumatoid Arthritis, IgA gammopathy, or Myelodysplastic Syndrome.
Early Skin Morphology & Subcutaneous Exam Violaceous retiform (net-like) purpura overlying rock-hard, woody, exquisitely tender subcutaneous plaques/nodules ("leather-like fat") that evolve into stellate black dry leathery eschars. Sudden, sharply demarcated bright red-to-purple ecchymotic plaques and hemorrhagic bullae on fat-rich areas (breasts, buttocks, thighs) turning into full-thickness necrosis within 24 to 48 hours. Erythema with ill-defined margins, rapidly spreading violaceous/hemorrhagic bullae, subcutaneous crepitus (gas), wooden induration extending beyond skin redness, and "dishwater" gray foul fluid. Livedo reticularis on lower legs/abdomen with purple/blue necrotic toes ("blue toe syndrome") despite palpable pedal pulses. Starts as a sterile pustule or inflammatory nodule after minor trauma (pathergy) that rapidly breaks down into a purulent ulcer with a boggy, undermined, violaceous-gunmetal overhanging border.
Systemic Toxicity & Fever at Onset Afebrile initially (pure ischemic infarction with 10/10 burning pain); fever/sepsis occurs later when the black eschar ulcerates and becomes secondarily infected. Afebrile; acute pain in the demarcated plaque without systemic septic shock. Fulminant Septic Shock from Hour 1: High fever (or hypothermia), severe tachycardia, hypotension, delirium, lactic acidosis, and LRINEC score >= 6. Subacute low-grade fever, eosinophilia (in 60% to 80%), eosinophiluria, transient hypocomplementemia, and stepwise subacute renal failure 1 to 4 weeks post-angiogram. Variable fever/leukocytosis, but wound cultures are completely sterile; expands rapidly if surgically debrided.
Imaging & Histopathology Hallmarks Plain X-ray (Mammography-technique): Shows fine arborizing/net-like calcifications of small subcutaneous arterioles (< 0.5 mm); Von Kossa / Alizarin Red stain: Medial calcification + intimal hyperplasia of dermal/fat arterioles + fibrin thrombi. Zero arteriolar calcification on X-ray or biopsy; biopsy shows fibrin thrombi occluding dermal capillaries and post-capillary venules with diffuse dermal hemorrhage. CT or bedside ultrasound shows fascial gas/fluid tracking along deep muscle fascia; surgical "finger test" shows zero resistance and non-bleeding gray fascia. Biopsy of muscle or skin shows biconvex needle-shaped "cholesterol clefts" inside small arteries (where lipid crystals dissolved during tissue processing). Biopsy shows a dense sterile dermal infiltrate of mature neutrophils with zero arteriolar calcification and zero bacterial organisms.
Definitive Emergency Treatment Stop Warfarin/Ca/Vit D + Give Vitamin K1 + IV Sodium Thiosulfate (25 g 3x/wk with HD) + Low-Ca Dialysate HD + Cinacalcet + Avoid aggressive deep surgical debridement. Stop Warfarin immediately + IV Vitamin K1 + Therapeutic IV Unfractionated Heparin + Fresh Frozen Plasma or Protein C Concentrate. Immediate Emergency Operating Room Wide Radical Surgical Debridement + IV Vancomycin + Piperacillin-Tazobactam/Meropenem + Clindamycin. High-dose Statin therapy + supportive care + avoid repeat arterial catheterization and avoid starting warfarin. Corticosteroids systemic dose avo lenta (Prednisone 1 hatramin'ny 2 mg/kg na IV Methylprednisolone) na Cyclosporine / Infliximab + Fandrarana STRICT ny debridement chirurgie.

Fandrika diagnostika: Rahoviana no hialana amin'ny biopsy hoditra vs. Ahoana ny fanaovana biopsy telescoping azo antoka

  1. Rehefa ampy ny Diagnose klinika + tsy misy invasive sary (tsy ilaina biopsy): Amin'ny mararin'ny aretin'ny voa amin'ny dingana farany amin'ny dialyse izay misy takelaka retiforme mampanaintaina manaintaina mahazatra, nodules subcutaneous hazo, na eschars mainty stellate eo amin'ny kibo na fe, **Ny biopsy hoditra dia matetika tsy mampidi-doza ary mety hampidi-doza. Ny fanapahana amin'ny takelaka calciphylaxis ischemic dia mitondra 30 ka hatramin'ny 50 isan-jato ny risika hiteraka fery amin'ny pathergic, fanitarana ratra tsy manasitrana, ary sepsis mahafaty faharoa.
  2. High-Sensitivity Non-Invasive Imaging Alternatives:
  3. Plain Soft-Tissue Radiographs Using High-Resolution Mammography Technique: Reveals fine, lacy, arborizing (tree-branch or net-like) calcifications of small subcutaneous arterioles (< 100 to 500 micrometers) with a specificity approaching 90 percent.
  4. Technetium-99m (Tc-99m MDP) Three-Phase Bone Scintigraphy: Demonstrates avid radiotracer uptake inside inflamed, calcifying subcutaneous fat pads across the thighs, abdomen, and buttocks (sensitivity 89% to 97%).
  5. How to Perform a Biopsy Safely When Diagnosis Is Uncertain (Non-Uremic Cases): Never biopsy the necrotic black eschar center and avoid wide excisional wedge biopsies. Use a dermatopathologist-guided "Double-Punch" (Telescoping) Technique at the viable indurated periphery (a 6 mm punch tool to reach the dermis followed by a coaxial 4 mm punch tool advanced deep into subcutaneous fat) and request Von Kossa (silver nitrate) and Alizarin Red S calcium stains.

Step-by-step Hospital Protocol: Sodium Thiosulfate Dosing, Intralesional Rescue, Hyperbaric Oxygen, and Novel Therapies (SNF472)

1. Intravenous and Intralesional Sodium Thiosulfate (Na2S2O3) Protocols

  • Standard Intravenous Hemodialysis Dosing: Administer 25 grams (100 mL of a 25% solution) diluted in 100 mL of 0.9% normal saline intravenously over the final 30 to 60 minutes of each hemodialysis session, 3 times per week (for patients weighing under 60 kg, reduce to 12.5 to 18.75 grams to prevent severe metabolic acidosis and vomiting).
  • Dosing in Non-Uremic Calciphylaxis Patients: In patients with normal kidney function (eGFR > 60 mL/min), administer 12.5 to 25 grams IV infused over 60 minutes 3 to 5 times per week while closely monitoring serum bicarbonate, anion gap, calcium, and QT interval.
  • Intralesional Sodium Thiosulfate Injections: Ho an'ny plaque eo an-toerana na ny marary tsy mahazaka IV STS, ny dermatologists dia manindrona 1 ka hatramin'ny 3 mL amin'ny 250 mg/mL (25%) Sodium Thiosulfate natsofoka 1: 1 miaraka amin'ny 1% Lidocaine (tsy misy epinephrine) amin'ny sisin-tany mavitrika indray mandeha isan-kerinandro. Aza ampidirina amin'ny intraperitoneal na oviana na oviana ny STS (miteraka peritonitis simika).

2. Controlling Secondary Hyperparathyroidism and Hyperbaric Oxygen Therapy (HBOT)

  • Calcimimetics Over Parathyroidectomy: If intact parathyroid hormone (iPTH) exceeds 300 pg/mL, start oral Cinacalcet (Sensipar, 30 to 180 mg/day) or intravenous Etelcalcetide (Parsabiv, 2.5 to 5 mg IV 3x/week post-HD). The EVOLVE trial showed cinacalcet reduces calciphylaxis incidence by 69% to 75%. Reserve urgent surgical parathyroidectomy for refractory hyperparathyroidism (iPTH > 500 to 1,000 pg/mL) with persistent hypercalcemia. Off-label IV bisphosphonates (pamidronate) and hexasodium fytate (SNF472) inhibit hydroxyapatite crystal growth in refractory cases.
  • Hyperbaric Oxygen Therapy (HBOT) and Safe Wound Care: Because calciphylaxis ulcers have severe hypoxia (transcutaneous PO2 < 20 mmHg), HBOT at 2.0 to 2.5 ATA for 90 minutes daily (20 to 40 sessions) restores tissue oxygenation and stimulates angiogenesis. Leave dry, non-infected black eschars intact as a biological dressing; use gentle enzymatic collagenase ointment, hydrogel dressings, or sterile medical maggot therapy (Lucilia sericata) for slough removal.

Never Prescribe Morphine, Codeine, or Meperidine for Calciphylaxis Pain in Kidney Failure

Administering Morphine, Codeine, Hydrocodone, or Meperidine (Pethidine) to a dialysis patient is dangerous because the kidneys cannot excrete morphine-6-glucuronide (which causes delayed respiratory arrest) or normeperidine (which causes seizures). Always use IV/Transdermal Fentanyl, Methadone, or Buprenorphine paired with low-dose post-dialysis Gabapentin or Pregabalin.

Ny fampahavitrihana ny ekipan'ny Calciphylaxis interdisciplinary aloha dia manatsara ny fahavelomana

Activating a coordinated team of nephrology, dermatology, specialized wound care, pain/palliative medicine, and renal nutrition on Day 1 reduces septic mortality and ensures humane pain control during ulcer healing.

Laharana vonjy taitra isam-paritra sy protocole masoivoho

  • United States and Canada: Dial 911 immediately for any dialysis patient with rapidly expanding necrotic ulcers, fever, hypotension, or intractable ischemic pain. Physicians can consult the Massachusetts General Hospital (MGH) Multidisciplinary Calciphylaxis Program and KDIGO CKD-MBD guidelines.
  • United Kingdom: Dial 999 or proceed to an NHS Emergency Department / Renal Unit under UK Kidney Association (UKKA) and British Association of Dermatologists (BAD) calciphylaxis protocols.
  • European Union, Australia, and Asia-Pacific: Dial 112 across the EU (European Calciphylaxis Network [EuCalNet]), 000 in Australia / 111 in New Zealand (KHA-CARI), or 119 / 995 / 999 across Asia-Pacific.

Fanontaniana apetraka matetika

How is Calciphylaxis different from ordinary Peripheral Arterial Disease (PAD) in a patient on dialysis?

In ordinary Peripheral Arterial Disease (PAD), cholesterol plaques narrow the large, named arteries of the legs, causing cramping calf pain when walking, absent foot pulses, and ulcers on the toes or heels. In Calciphylaxis (Calcific Uremic Arteriolopathy), the large arteries of the legs are often completely open and the patient's ankle and foot pulses are still strong. Instead, calciphylaxis selectively turns microscopic arterioles (under 0.6 millimeters wide) inside deep subcutaneous fat pads into bone, followed by acute blood clots that plug those tiny vessels. That is why calciphylaxis typically strikes fat-rich areas like the abdomen, thighs, buttocks, and breasts, causing a purple net-like rash and black leathery scabs despite normal foot pulses.

Why does taking the blood thinner Warfarin (Coumadin) trigger Calciphylaxis, and why must it be stopped on Day 1?

To keep calcium and phosphate in the blood from turning into bone inside our arteries, the muscle cells lining tiny blood vessels produce a protective protein shield called Matrix Gla Protein (MGP), which requires Vitamin K to switch it on. Warfarin blocks Vitamin K in the liver and inside blood vessel walls, shutting down active Matrix Gla Protein by more than 80 percent. Without its MGP shield, the tiny arterioles in a dialysis patient's fat tissue rapidly calcify into brittle bone, raising the risk of calciphylaxis up to 10-fold. Stopping warfarin immediately, giving Vitamin K1 supplements to turn MGP back on, and switching to a non-vitamin-K blood thinner (such as renal-dosed apixaban) is mandatory on Day 1.

How is Calciphylaxis distinguished from Acute Warfarin-Induced Skin Necrosis (WISN)?

Acute Warfarin-Induced Skin Necrosis (WISN) strikes within the first 3 to 10 days after starting high-dose warfarin without a heparin bridge: because warfarin drops natural anticoagulant Protein C (half-life 6 hours) much faster than clotting Factor II (half-life 60 hours), the patient enters a temporary hypercoagulable state that clots dermal veins and capillaries, with zero calcium in the blood vessels. Calciphylaxis, by contrast, develops after months or years of chronic warfarin use or kidney dialysis, involves chronic bony calcification of tiny arterioles, and is treated with intravenous Sodium Thiosulfate and stopping warfarin.

How does Intravenous Sodium Thiosulfate (STS) heal Calciphylaxis ulcers and relieve pain?

Intravenous Sodium Thiosulfate (infused at 25 grams over the last hour of each hemodialysis session three times a week) fights calciphylaxis in three ways: it chemically chelates insoluble calcium deposits inside arteriolar walls into ultra-soluble calcium thiosulfate that washes out through the dialysis machine, acts as a potent antioxidant in starved skin, and regenerates endothelial nitric oxide to dilate surviving micro-vessels, often relieving excruciating burning pain within 7 to 14 days.

Why is aggressive surgical debridement dangerous during early active Calciphylaxis?

In active calciphylaxis, the surrounding purple skin and underlying fat are severely starved of blood flow because the microscopic arteriolar network is calcified and clotted. Cutting into that ischemic border with a scalpel triggers pathergy and acute microvascular thrombosis, causing the newly cut edges to die and turn black. Unless an eschar has wet pus or spreading bacterial sepsis trapped underneath it that must be drained, specialists use gentle enzymatic ointments, hydrogel dressings, sterile medical maggots, and hyperbaric oxygen therapy while Sodium Thiosulfate clears the vascular calcium.

Loharano sy tari-dalana ofisialy

  • New England Journal of Medicine (NEJM) Clinical Practice Review (Nigwekar SU, Thadhani R, Brandenburg VM): Calciphylaxis: Pathogenesis of Calcific Uremic Arteriolopathy, Matrix Gla Protein Inhibition by Warfarin, Diagnostic Triage, and Intravenous Sodium Thiosulfate Protocol.
  • Kidney Disease: Improving Global Outcomes (KDIGO): Clinical Practice Guideline Update for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
  • Massachusetts General Hospital (MGH) Calciphylaxis Program and American Society of Nephrology (ASN): Interdisciplinary Management Protocol for Uremic and Non-Uremic Calciphylaxis.
  • UK Kidney Association (UKKA), British Association of Dermatologists (BAD), and European Calciphylaxis Network (EuCalNet): Clinical Guidance on Calcific Uremic Arteriolopathy in Dialysis Patients.

Manaova taranja fanampiana voalohany voamarina ary manaova hevitra amin'ny matihanina

This guide provides emergency medical recognition and educational triage information and does not replace professional nephrological, dermatological, vascular, or surgical care. To learn practical skills in recognizing sepsis, managing bleeding, and performing cardiopulmonary resuscitation, take a certified first aid course through the Red Cross, St John Ambulance, or a local provider.

Mpitarika mifandraika